BIOCRYST PHARMACEUTICALS INC
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
BCRX$7.63-0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
INDEX
| Page No. | |
|---|---|
| Cautionary Note Regarding Forward-Looking Statements | i |
| Risk Factor Summary | ii |
| Part I. Financial Information | 1 |
| Item 1. Financial Statements: | 1 |
| Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 | 1 |
| Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2024 and 2023 | 2 |
| Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023 | 3 |
| Condensed Consolidated Statements of Stockholders’ Deficit for the Three and Six Months Ended June 30, 2024 and 2023 | 4 |
| Notes to Condensed Consolidated Financial Statements | 6 |
| Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 30 |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk | 42 |
| Item 4. Controls and Procedures | 43 |
| Part II. Other Information | 45 |
| Item 1A. Risk Factors | 45 |
| Item 5. Other Information | 73 |
| Item 6. Exhibits | 75 |
| Signatures | 77 |
| EX-10.2 | |
| EX-10.3 | |
| EX-10.4 | |
| EX-31.1 | |
| EX-31.2 | |
| EX-32.1 | |
| EX-32.2 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.